Table 3.
HBV prophylaxis and outcome of patients receiving Anti-HBc-positive donors livers
| Received NUC | Not received NUC | Total | |
|---|---|---|---|
| Number of patients | 18 | 2 | 20 |
| Lamivudine | 10 (1 switched to ETV) | N/A | 10 |
| Entecavir | 8 | N/A | 8 |
| Post-LT HBV infection | 0/16a | 2/2 | 2/18 |
| Outcome | |||
| Alive | 13 | 2 | 15 |
| Dead | 4 | 0 | 4 |
| Loss to follow up | 1 | 0 | 1 |
| Duration of follow up (months) | |||
| Mean ± SD | 33.9 ± 22.9 | 24 ± 2.8 | 32.8 ± 21.8 |
| Median (range) | 32 (1–75) | 24 (22–26) | 27.5 (1–75) |
| Follow up ≥ 12 months | 14 | 2 | 16 |
| Follow up ≥ 36 months | 7 | 0 | 7 |
| Follow up ≥ 60 months | 3 | 0 | 3 |
Data expressed as number unless specified otherwise
HBV hepatitis B virus, NUC nucleos(t)ide analog, ETV entecavir, N/A not applicable
aTwo patients died before HBV markers were tested